Osteogenesis and angiogenesis are two closely correlated processes during bone growth, development, remodelling and repair. Vascular endothelial growth factor (VEGF) is an essential mediator during the process of angiogenesis. Based on an extensive literature search, which was carried out using the PubMed database and the keywords of osteogenesis, VEGF, endochondral ossification and intramembranous ossification, this manuscript reviews the role of VEGF in ossification, with emphasis on its effect in endochondral and intramembranous ossification. Osteogenesis and angiogenesis are closely correlated processes. VEGF acts as an essential mediator during these processes. It not only functions in bone angiogenesis but also in various aspects of bone development.
INTRODUCTION
Bone formation can occur through two distinct pathways, namely, endochondral ossification and intramembranous ossification.
1-2
During development of some skull and facial bones or during bone repair, if bone segments are stabilized, mesenchymal precursor cells differentiate directly into bone-forming osteoblasts in a process called intramembranous ossification. This process of ossification occurs in many locations of the skeleton and includes formation of flat bones of the cranium, facial bones and addition to shafts of many other bones. During this process, osteoblasts lay down bone matrix forming spicules. Initially, these spiculae lay down trabecular bone, which is eventually replaced with lamellar.
1 Alternatively, during development of long bones and vertebrae or bone repair in a biomechanically unstable environment, bone formation occurs via a cartilage intermediate in a process called endochondral ossification. 3 During endochondral ossification, mesenchymal cells differentiate to chondrocytes. Vascular invasion and chondrocytes proliferate in a coordinated process that lengthens the bone. 2 Osteogenesis and angiogenesis are two closely correlated processes during bone growth, development, remodelling and repair. 4 Vascular endothelial growth factor (VEGF) is an essential mediator during the process of angiogenesis. Disruption of a single VEGF allele causes embryonic lethality because of defective vasculogenesis, angiogenesis and large vessel formation. [5] [6] Postnatal ablation of VEGF leads to abnormal organs development because of the reduced vascularisation and angiogenesis. 7 Except these effects on angiogenesis, VEGF works in both processes of endochondral ossification and intramembranous ossification [8] [9] [10] [11] [12] and acts as an essential mediator during these processes. It is involved not only in bone angiogenesis, but also in various aspects of bone development, including chondrocyte differentiation, osteoblast differentiation and osteoclast recruitment. This article focuses predominately on the role of VEGF in the above two ossification processes.
MATERIALS AND METHODS
A literature search was carried out using PubMed and the keywordsosteogenesis; VEGF; endochondral ossification; and intramembranous ossification. Articles that only described the effect of VEGF on angiogenesis were excluded. A total of 44 references were finally included in this manuscript.
VEGF AND ITS RECEPTORS
VEGF is a specific mitogen for vascular endothelial cells. It was first identified as an endothelial-specific growth factor from bovine pituitary follicular cells by Ferrara and Davis Symth. 13 The VEGF family consists of seven members, namely, placenta growth factor, VEGF-A, -B, -C, -D, -E and -F. [13] [14] They all share a common structure of eight characteristically spaced cysteine residues in a VEGF homology domain. VEGF-A is the most abundant form and is therefore commonly used in studies investigating the biological effects of VEGF. 15 Thus, VEGF is commonly referred to as VEGF-A. 16 Using this convention, the term VEGF mentioned in this review refers to VEGF-A.
In the osteogenesis-angiogenesis coupling, hypoxia-inducible factor is one of the key upstream regulators of VEGF. Upregulation of hypoxia-inducible factor can be induced not only by the decrease of oxygen tension, [17] [18] but also by other stimulus, such as insulin-like growth factor-1. [19] [20] Recent study indicated that changes of the level of hypoxia-inducible factor can alter the level of VEGF significantly and change the bone mass dramatically. 21 The biological effects of VEGF are mediated by specific tyrosine kinase receptors (VEGFRs), i.e., Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1) and Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). Both Flt-1 and KDR can be phosphorylated on tyrosine residues, but show different patterns of potential intracellular substrates in the in vitro immune complex kinase assay and they also mediate different cellular responses. KDR, rather than Flt-1, was found to be the major mediator of essential functions such as In addition, neuropilin-1 and neuropilin-2 are receptors for semaphorins, but they also have been shown to serve as co-receptors for VEGF. 24 
EFFECTS OF VEGF ON BONE CELLS
Bone is a dynamic tissue in which bone resorption and formation (bone remodelling) occur in a regulated manner under the influence of systemic hormones and local factors. Osteoclasts, the multinucleated giant cells that resorb bone, develop from haematopoietic cells of the monocyte/macrophage lineage. The osteoblast is a type of mononucleate cell, arising from osteoprogenitor cells located in the periosteum and the bone marrow that is responsible for bone formation. Besides producing osteoid, which is composed mainly of type I collagen, osteoblasts are also responsible for mineralisation of the osteoid matrix. Furthermore, osteoblasts and bone marrow stromal cells support osteoclast development via the mechanism of cell-to-cell interaction with osteoclast progenitors.
EFFECTS OF VEGF ON OSTEOBLASTS
VEGF has been implicated in various aspects of osteoblast function. Two studies have shown a dose-dependent chemoattractive effect of VEGF on primary human osteoblasts 25 and human mesenchymal progenitor cells. 26 In addition to its effect on cell migration, VEGF stimulates cell proliferation by up to 70%. 26 It was found that VEGF directly promotes differentiation of primary human osteoblasts in vitro by increasing nodule formation and alkaline phosphatase activity in a dosedependent manner. 27 Also reported is that VEGF was expressed at low levels at the beginning of osteoblast differentiation and that its expression was strongly increased only during terminal differentiation and reached maximum expression during the period of mineralisation. 28 Thus, VEGF plays an essential role in the regulation of bone remodelling by stimulating osteoblast differentiation.
Mayr-Wohlfart et al. also revealed increased expression of Flt-1 and KDR on human osteoblasts. 25 An in vitro kinase assay failed to demonstrate activation of KDR upon stimulation with VEGF, which is consistent with the idea that the effect of VEGF on primary human osteoblasts is mediated via Flt-1. 25 
EFFECTS OF VEGF ON OSTEOCLASTS
Recent discovery of receptor activator nuclear factor kappa b ligand (RANKL)-RANK interaction confirms the hypothesis that there is a direct contact between osteoblasts and osteoclasts and osteoblasts play an essential role in osteoclast differentiation. Osteoblasts express RANKL as a membrane-associated factor. Osteoclast precursors that express RANK, a receptor for RANKL, recognize RANKL through the cell-cell interaction and differentiate into osteoclasts. 29 Yasuda et al. also identified another key factor for osteoclastogenesis, osteoprotegrin. 30 Osteoprotegrin is produced by osteoblasts or stromal cells and binds to RANKL as a decoy receptor, therefore preventing interaction between RANKL with RANK. Thus, osteoclast differentiation is inhibited by osteoprotegrin.
Min et al. have shown that VEGF can significantly increase both the expression of RANK mRNA and surface protein in human microvascular endothelial cell lines. 31 In addition, they revealed that VEGF mainly enhances RANK expression in endothelial cells through Flk-1/ KDR-protein kinase C-ERK signaling pathway, suggesting that VEGF plays an important role in modulating the angiogenic action of RANKL under physiological or pathological conditions. Yao et al. also found that the combination of VEGF and a low dose of colonystimulating factor-1 can upregulate the RANK expression in osteoclast precursors that is needed for osteoclastogenesis. 32 Nakagawa et al. suggested that VEGF is involved in osteoclastic recruitment, differentiation and enhancement of osteoclastic bone-resorbing activity in cultured rabbit mature osteoclasts. 33 
EFFECTS OF VEGF ON ENDOCHONDRAL OSSIFICATION
Endochondral ossification (also referred to as intracartilaginous ossification) plays a major role in bone formation. It is an essential process during mandibular condylar growth, rudimentary formation and growth of long bones, and the healing of bone fractures. Unlike intramenbranous ossification, cartilage, an avascular tissue is present and replaced by bone during endochondral ossification. Endochondral ossification occurs as chondrocytes undergo proliferation, hypertrophy, cell death and osteoblastic replacement. VEGF has been indicated to serve as an important mediator during the process due to its ability to regulate blood vessel invasion (neovascularisation) into hypertrophic cartilage [34] [35] [36] ( Figure 1 ). The invading blood vessels bring undifferentiated mesenchymal cells into the mineralisation front and later differentiate into osteoblasts and engage in osteogenesis. 34 Also, a recent study by Bluteau et al. for the first time showed that chondrocytes can secrete four members of the VEGF family. 37 VEGF-A, -B, -C and-D were detected and upregulated at the mRNA and protein levels during chondrogenic differentiation of primary chondrocytes in the ATDC5 chondrogenic cell line. This suggests that these factors play an essential role during chondrogenesis. Zelzer et al. VEGF impacts on endothelial cells and initiates the angiogenesis process which recruits original mesenchymal cells migrate to cartilage or subperioeteal connective tissue through the neonatal blood vessels. During the process of endochondral ossification, the mesenchymal cells differentiate into chondrocytes, and undergo chondrocytes hypertrophy. Then, the process of bone formation is initiated. On the other hand, during the process of intramembranous ossification, the mesenchymal cells which migrate to the subperioeteal connective tissue differentiate into osteoblasts directly and initiate the process of bone formation. VEGF upregulates the expression of growth factors and cytokines in endothelial cells and plays an important role during the process of intramembranous ossification. VEGF, vascular endothelial growth factor.
The
role of VEGF in blood vessel invasion into hypertrophic cartilage during bone development. 38 More importantly, they described for the first time a connection between VEGF and chondrocyte survival during skeletal development.
During mandibular growth, the condyle undergoes endochondral ossification and the condylar cartilage serves as a template for bone formation. Condylar growth involves a multistage process of cell differentiation, defined by molecules that are synthesized by cells in the condyle. 34 VEGF is expressed at high levels in hypertrophic chondrocytes in the mandibular condyle of growing and adult rats. 34, 39 Maximum levels of VEGF expression precede the maximum level of new bone formation in the condyle. This indicates a close correlation between vascularisation and bone formation. [35] [36] Gene therapy explored in the condylar area by Rabie and co-workers, has shown that recombinant adeno-associated virus-mediated VEGF is an efficient delivery system to induce mandibular condylar growth [9] [10] [11] . Here we see a direct cause and effect. This exogenous VEGF leads to significant condylar growth. [35] [36] [40] [41] [42] Data from Cortina-Ramírez and Chimal-Monroy suggest differential effects of VEGF on different joints during development. 41 They evaluated VEGF effects on joints by implanting VEGF beads in the presumptive limb joints of chick embryos. The wrist and elbow showed partial and complete fusions. They found that VEGF inhibited joint formation when it was applied after transforming growth factor-beta.
The spheno-occipital synchondrosis is an important growth center of the craniofacial skeleton. It forms an important link between the cranial vault and facial skeleton and can influence the positions of the maxilla and mandible. 42 It undergoes endochondral ossification and contributes largely to the expansion of the ossification centres and growth of the cranial base during the postnatal period. Lei et al. identified factors that regulate endochondral ossification in the spheno-occipital synchondrosis through their experiment on mice, in which they found that mechanical stress applied to the spheno-occipital synchondrosis elicits core-binding factor subunit alpha-1 expression and subsequently upregulates the expression of VEGF. 43 Both factors play an important role in growth of the spheno-occipital synchondrosis.
As hypertrophic chondrocytes are avascular, these cells are a potential source of VEGF within the growth plate. To determine the role of VEGF in endochondral bone formation, Gerber et al. inactivated VEGF through the systemic administration of a soluble receptor chimeric protein (Flt-(1-3)-IgG) to 24-day-old mice. 44 Blood vessel invasion was almost completely suppressed, concomitant with impaired trabecular bone formation and expansion of the hypertrophic chondrocyte zone. Recruitment and/or differentiation of chondroclasts, which express gelatinase B/matrix metalloproteinase-9, and resorption of terminal chondrocytes decreased. Although proliferation, differentiation and maturation of chondrocytes were apparently normal, resorption was inhibited. Cessation of the anti-VEGF treatment was followed by capillary invasion, restoration of bone growth, resorption of the hypertrophic cartilage and normalisation of the growth plate architecture. These findings indicate that VEGFmediated capillary invasion is an essential signal that regulates growth plate morphogenesis and triggers cartilage remodelling. Thus, VEGF is a potential coordinator of chondrocyte death, chondroclast function, extracellular matrix remodelling, angiogenesis and bone formation in the growth plate. More investigates are needed to prove this hypothesis.
Healing of fractures is dependent on vascularisation of bone, which is in turn promoted by VEGF. In skeletogenesis, which is tightly linked to angiogenesis, VEGF promotes the vascularisation of the growth plate and transformation of cartilage to bone. Street et al. determined whether VEGF is required for bone repair by inhibiting VEGF activity during secondary bone healing via a cartilage intermediate/endochondral ossification in a novel mouse model. 27 Femoral fractures were used as models of endochondral ossification. Fracture repair occurred in a series of events, involving an initial inflammatory phase, a soft callus phase, a hard callus phase and a remodelling phase. VEGF inhibition in mice by Flt-IgG, a soluble VEGF receptor blocker, disrupted repair of femoral fractures and impaired new bone formation. Their results provide evidence that VEGF activity is essential for conversion of soft cartilaginous callus to a hard bony callus and mineralisation in response to bone injury. Geiger et al. based on their experiment on rabbits, showed that VEGF-gene-activated matrix, led to a significant increase in vascularisation and bone regeneration in large segmental defects. 45 Thus, VEGF-gene-activated matrix can serve as an appropriate tool to promote angiogenesis, osteogenesis and bone healing. Li et al. demonstrated enhanced healing of a segmental defect in the long bone of rabbits using the cell-based VEGF gene transfer without viral vectors. 12 Their findings proved that this delivery method can be effective in management of clinical situations where vascularity is compromised and neovascularisation is to be encouraged, such as fractures with bone loss without the complications regarding viral vectors.
Peng et al. showed interaction between angiogenic and osteogenic factors in bone formation and bone healing. 46 They discovered that the combination of VEGF and bone morphogenetic protein 4 is able to recruit more mesenchymal stem cells to enhance cell survival and to induce cartilage formation in the early stages of endochondral bone formation. Further, the beneficial effect of VEGF on bone healing was found to be dependent on the ratio of VEGF to bone morphogenetic protein 4. Table 1 summarizes the effects of VEGF on endochondral ossification.
EFFECTS OF VEGF ON INTRAMEMBRANOUS OSSIFICATION
Intramembranous ossification is a process whereby the formation of bone tissue occurs directly from connective tissue without a preliminary cartilage stage. A good example occurs in the glenoid fossa which is formed when mesenchymal cells directly differentiate into osteoblasts before ultimately forming bone.
1 Experimental studies on rats have shown that mechanical strain caused by forward mandibular positioning stimulates the bone cells in the subperiosteal connective tissue of the glenoid fossa to secrete VEGF. During natural growth and forward mandibular positioning, VEGF expression and new bone formation were the highest in the posterior region of the glenoid fossa. [35] [36] The identification of the temporal sequence of the cellular response revealed that the mesenchymal cells in the posterior region of the glenoid fossa were oriented in the direction of the pull. 47 VEGF enhances neovascularisation, which in turn increases the number of mesenchymal cells in the perivascular connective tissue (Figure 1) . VEGF also stimulates the vascular endothelial cells to secrete growth factors and cytokines that influence the differentiation of mesenchymal cells to enter the osteogenic pathway and engage in osteogenesis 48 ( Figure 1) . Furthermore, the greatest amount of VEGF expression precedes the greatest increase in new bone formation. Therefore, it has been concluded that an increase of VEGF is spatially and temporally related to the amount of new bone formation in the posterior glenoid fossa. [35] [36] Bone repair is a multistep process which involves migration, proliferation, differentiation and activation of several cells types. Study from Tatsuyama et al. 49 on fracture repair in bone indicates that this
The role of VEGF in ossification YQ Yang et al 66 process is complex, occurring through several steps and involving various growth factors including VEGF. Bone growth and bone repair are somehow regulated in a similar manner and thus, VEGF should have a similar effect during bone repair. 8 Repair of large bony defects in the craniofacial region represent a major challenge for the surgeon, since autogenous graft material from patients may not be available in sufficient amounts. It has been shown that addition of VEGF to demineralized intramembranous bone matrix (DBMIM) improves the quality and quantity of newly formed bone in the grafted site, thus indicating that VEGF1DBMIM is a good graft material. It is both easily obtainable and could eliminate the need to harvest bone from the patient. Its future application, however, will require further clinical evidence.
Results from Street et al. on mice also show the role of VEGF in intramembranous ossification. 27 They have shown direct bone repair through intramembranous ossification in a novel mouse model (tibial cortical bone defects). Inhibition of VEGF by Flt-IgG treatment, just as in the femoral fracture model, had distinct effects on bone healing of cortical bone defects. The persistence of unresorbed, unmineralized fracture haematoma at 7 days and the persistence of woven bone at 14 days indicate remodelling defects in Flt-IgG-treated mice. They found that the effects of Flt-IgG on intramembranous bone formation (cortical defects were more prominent at the earlier (7 days) than later (14 days) time point) were due to the fact that intramembranous ossification does not involve a cartilage intermediate. Thus, they suggested that a slow release formulation of VEGF, applied locally at the site of bone damage, can be an effective therapy to promote human bone repair.
Another example of the role of VEGF in intramembranous ossification is observed in distraction osteogenesis, a surgical therapy used in the treatment of skeletal injuries and deformities and in the correction of limb length abnormalities. 50 Bone formation during distraction osteogenesis occurs primarily through an intramembranous process. Investigators observed close correlation between optimal angiogenic response and the rate of distraction and speculated that it is this characteristic that drives bone formation through the intramembranous pathway. 51 To elucidate the functional role of VEGF signaling during bone formation in distraction osteogensis, Jacobsen et al. used two blocking antibodies MF-1 (anti-Flt-1) and DC101 (anti-KDR) to specifically disrupt the activities of KDR and Flt-1. 52 The results showed that both KDR and Flt-1 play important roles in neovascularisation and bone formation during distraction osteogenesis. Table 2 summarizes the effects of VEGF on intramembranous ossification. The role of VEGF in ossification YQ Yang et al 67
CONCLUSION
The evidence from a large amount of research has shown conclusively that VEGF is able to promote ossification by either inducing neovascularisation or by directly affecting bone cells. VEGF can stimulate ossification through the two pathways of endochondral ossification and intramembranous ossification.
